A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT01225393

Public ClinicalTrials.gov record NCT01225393. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patient With Active Rheumatoid Arthritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter study enrolling patients with active rheumatoid arthritis (RA).

Study identification

NCT ID: NCT01225393
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Genentech, Inc.; Industry
Enrollment: 211 participants

Conditions and interventions

Conditions

Rheumatoid Arthritis

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 31, 2010
Primary completion: Jun 30, 2012
Completion: Not listed
Last update posted: Nov 1, 2016

Started 2010

United States locations

U.S. sites: 14
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
Not listed	Anniston	Alabama	36207	—
Not listed	Birmingham	Alabama	35216	—
Not listed	Peoria	Arizona	85381	—
Not listed	Los Angeles	California	90033	—
Not listed	Upland	California	91786	—
Not listed	Ormond Beach	Florida	32174	—
Not listed	Lexington	Kentucky	40515	—
Not listed	Kalamazoo	Michigan	49009	—
Not listed	Flowood	Mississippi	39232	—
Not listed	Reno	Nevada	89502	—
Not listed	Charleston	South Carolina	29406	—
Not listed	San Antonio	Texas	78217	—
Not listed	Chesapeake	Virginia	23320	—
Not listed	Clarksburg	West Virginia	26301	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01225393, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 1, 2016 · Synced Sep 24, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01225393 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →